A Typical Gartner’s Duct Cyst-Case Report Symptomatically Managed by Unani Drugs

Authors

  • Suboohi Mustafa
  • Saba Tarannum
  • Nasreen Ainuddin

Abstract

Gartner’s duct cysts develop from the vestigial remnants of mesonephric (Wolffian) ducts which most often develop during and after late adolescence. It is a rare disease entity; small cysts and asymptomatic cysts usually do not require any treatment. Symptomatic cysts are usually managed by procedures like cyst drainage or aspiration and intra-cystic tetracycline, whereas large cysts may be treated with surgical treatment. For small symptomatic cysts, Unani medicine may provide a safe conservative treatment. We represent the case of a 45 years old woman with a mass at the anterior vaginal wall confirmed with transvaginal ultrasound. In the case presented, the woman had mild symptoms of lower abdominal pain and sense of swelling. Conservative treatment with Unani drugs was given and the patient was found relieved even after one and half year of follow up. It may be concluded that Muhallil Advia like arqmako and arqkasni can be a safe option in the patients with mild symptoms and small sized Gartner’s duct cysts.

 

Keywords: Gartner’s duct, cyst, Wolffian duct, vaginal cysts, cystocele

 

Cite this Article

Suboohi Mustafa, Saba Tarannum, Nasreen Ainuddin. A Typical Gartner’s Duct Cyst-Case Report Symptomatically Managed by Unani Drugs. Research & Reviews: A Journal of Health Professions. 2020; 10(3): 10–13p.

Downloads

Published

2021-01-12

Issue

Vol. 10 No. 3 (2020)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.